Astrazeneca strikes exclusive licensing deal with Dizal Pharmaceutical.

• AstraZeneca
• 14 July 2026 08:20:10

Source: Sharecast

Zegfrovy has already received approval in the US and China for adults with locally advanced or metastatic non‑small cell lung cancer whose disease has progressed after platinum‑based chemotherapy. Around 80–85% of lung‑cancer patients globally have NSCLC.

Dizal recently reported positive results from its WU‑KONG28 Phase III trial in first‑line NSCLC with exon 20 insertion mutations, with the data presented as a late‑breaking oral abstract at the 2026 ASCO annual meeting and published in The New England Journal of Medicine.

Supported by those results, a supplemental NDA has been filed with both the US FDA and China's CDE, and the drug has received breakthrough therapy designation in the first‑line setting from both regulators.

Under the agreement, Astrazeneca will pay $600m upfront and up to $900m in development, regulatory and sales‑related milestones, with Dizal also receiving tiered royalties on global sales. The transaction was expected to close in the second half of 2026, subject to customary approvals, and will not affect Astrazeneca's 2026 financial guidance.

As of 0820 BST, Astrazeneca shares were down 0.56% at 12,540p.

Reporting by Iain Gilbert at Sharecast.com

See latest RNS at Investegate